Bone Density, Calcium, and the Heart: Why Osteoporosis and Cardiovascular Disease Are Connected

Osteoporosis and cardiovascular disease share a common hormonal origin in women. Estrogen withdrawal after menopause simultaneously accelerates osteoclast-mediated bone resorption and impairs endothelial nitric oxide production. In the Women’s Health Initiative, women with incident hip fracture had 2.4-fold higher cardiovascular death risk compared to those without fracture (HR 2.4, 95% CI 1.8-3.2). UK Biobank imaging data confirm that each standard-deviation decrease in bone mineral density correlates with stiffer arteries and elevated coronary heart disease mortality. Your DEXA scan is cardiovascular information.

The Skeleton Speaks First

Her DEXA showed -2.2 in her hip at 54. Her cardiologist said: low bone density and vascular calcification come from the same hormonal event. Your skeleton and your arteries are both trying to tell you something.

She had no chest pain. No shortness of breath. Her internist ordered the DEXA because her mother had fractured a hip at 67. The T-score came back at -2.2, crossing the threshold into osteoporosis. Standard practice would have stopped there: start bisphosphonates, add calcium, see you in two years.

But her physician understood something most do not. A T-score of -2.2 at age 54 is not only a bone problem. It is a systemic marker of hormonal vascular injury that began years earlier.

In the Women’s Health Initiative observational cohort, women who sustained hip fractures had a 2.4-fold increased risk of cardiovascular death compared to women without fractures (HR 2.4, 95% CI 1.8-3.2) Cauley 2015. This was not because fractures directly cause heart attacks. It was because the same biological clock that weakened their bones had been weakening their arteries for a decade. 5 / Solid

The UK Biobank imaging study of over 5,000 participants found that each standard-deviation decrease in bone mineral density associated with significantly stiffer arteries and higher coronary heart disease mortality Raisi-Estabragh 2020. The skeleton and the vasculature are not separate organ systems living in isolation. They are both downstream of estrogen.

This is the framework I call The Bone-Artery Axis: the recognition that osteoporosis and cardiovascular disease are two manifestations of a single hormonal vascular event. Your DEXA scan is not just orthopedic information. It is cardiovascular information. And your cardiologist should see it.

The Hormonal Driver: One Deficit, Two Diseases

Estrogen does not simply make women fertile. Estrogen maintains vascular tone and bone density through two parallel mechanisms that collapse simultaneously at menopause.

In the vasculature, estrogen activates endothelial nitric oxide synthase (eNOS). Nitric oxide relaxes arterial smooth muscle, inhibits platelet aggregation, and suppresses inflammatory adhesion molecules. When estrogen falls, eNOS activity drops. Arteries stiffen. Endothelial inflammation rises. The atherosclerotic process accelerates.

In bone, estrogen suppresses osteoclast differentiation by inhibiting RANKL, the receptor activator of nuclear factor kappa-B ligand. RANKL tells osteoclasts to resorb bone. Estrogen keeps RANKL in check. When estrogen falls, RANKL rises unopposed. Osteoclasts proliferate. Bone resorption exceeds bone formation. The skeleton thins.

These are not two separate diseases that happen to affect menopausal women. They are one disease with two organ targets. The shared mechanism explains why risk factors for osteoporosis and cardiovascular disease overlap so completely: age, smoking, diabetes, physical inactivity, chronic inflammation Elnour 2022.

A 2024 bidirectional Mendelian randomization study confirmed genetic causality in one direction: genetically predicted lower bone mineral density causally increases coronary heart disease risk Guo 2024. The association is not confounding. It is biology. 4 / Promising

Women don’t die from what they have. Women die from what they hold. And what they hold, at menopause, is a hormonal deficit that attacks skeleton and vasculature simultaneously, often without symptoms in either organ system until the damage is advanced.

The Calcium Paradox: When Supplements Become the Problem

Here is where standard medical advice becomes dangerous.

A woman is diagnosed with osteoporosis. Her physician prescribes calcium supplements, 1,000-1,200 mg daily, along with vitamin D. This has been the standard of care for three decades. The logic seems sound: bones need calcium, so give calcium.

But a 2010 meta-analysis of 11 randomized trials involving over 12,000 participants found that calcium supplements at doses of 500 mg or more daily were associated with a 27% increased risk of myocardial infarction (RR 1.27, 95% CI 1.01-1.59) and a 20% increased risk of stroke (RR 1.20, 95% CI 1.00-1.43) Bolland 2010. 5 / Solid

The risk was highest in women who already consumed adequate dietary calcium. Adding supplements on top of a calcium-rich diet did not strengthen bones further. It deposited calcium in arterial walls.

This phenomenon is called the calcium paradox: bones lose calcium while arteries gain it, often in the same patient, sometimes accelerated by the same supplement.

The mechanism centers on vitamin K2, specifically the MK-7 form. Vitamin K2 activates matrix Gla protein (MGP), a calcium-binding protein produced by vascular smooth muscle cells. Active MGP binds free calcium in the bloodstream and prevents its deposition in arterial walls. At the same time, vitamin K2 activates osteocalcin, which directs calcium into bone matrix Shea 2012.

Without adequate vitamin K2, MGP remains inactive. Calcium has nowhere to go except soft tissue. The arteries calcify. The bones stay thin. The supplement intended to help becomes part of the problem.

Most Western diets are deficient in vitamin K2. It is found in fermented foods (natto, aged cheese), egg yolks, and organ meats. The average American consumes perhaps 30-50 mcg daily. Therapeutic doses in cardiovascular studies range from 180-360 mcg.

This does not mean calcium supplements are categorically harmful. It means calcium supplementation without K2 is incomplete biology. And it means high-dose calcium supplements in women with adequate dietary intake may do more vascular harm than skeletal good.

Arterial Calcification: The Bone You Don’t Want

Arterial calcification is not simply plaque buildup. It is bone formation in the wrong location.

Vascular smooth muscle cells, under conditions of chronic inflammation and phosphate overload, can transdifferentiate into osteoblast-like cells. They express the same markers as bone-forming cells: RUNX2, alkaline phosphatase, osteocalcin. They deposit hydroxyapatite, the same mineral that gives bone its hardness. The arterial wall becomes literally ossified.

This process, called vascular calcification, stiffens arteries and increases pulse wave velocity. The heart must pump harder against a rigid vascular tree. Left ventricular hypertrophy follows. Coronary perfusion during diastole decreases. The same calcification that shows up on a coronary artery calcium (CAC) score represents active bone metabolism in the vascular wall Tadic 2025. 4 / Promising

The tragic irony: the calcium leaving bones often ends up in arteries. The same patient with a T-score of -2.5 may have a CAC score of 400. Her skeleton is calcium-depleted. Her coronary arteries are calcium-loaded. This is not random distribution. This is failed calcium routing driven by vitamin K2 insufficiency, vitamin D status, parathyroid hormone levels, and chronic inflammatory signaling.

Coronary artery calcium scoring should be part of the evaluation for any woman diagnosed with osteoporosis. Not as a nice-to-have. As a clinical necessity. The DEXA and the CAC score are two views of the same hormonal vascular event.

Bisphosphonates and the Heart: What the Data Show

Bisphosphonates (alendronate, risedronate, zoledronic acid) are first-line therapy for osteoporosis. They inhibit osteoclasts, reduce bone resorption, and decrease fracture risk by 40-70% depending on skeletal site. But do they affect the heart?

The cardiovascular data are mixed but generally reassuring.

Bisphosphonates inhibit farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway. This is the same pathway targeted by statins. In vitro, bisphosphonates reduce vascular smooth muscle cell calcification. In animal models, they reduce aortic calcium content Paccou 2017.

Human observational studies suggest neutral to mildly beneficial cardiovascular effects. A Danish cohort study found no increased cardiovascular risk with bisphosphonate use. Some studies suggest reduced arterial stiffness and lower CAC progression in bisphosphonate-treated patients compared to untreated controls. 3 / Early

Bisphosphonates are not prescribed for cardiovascular protection. But women should not avoid osteoporosis treatment out of cardiac concern. Treating bone loss does not appear to harm the heart. It may marginally help.

The more important message: treating osteoporosis is cardiovascular risk management. Reducing fracture risk keeps women mobile, reduces hospitalization, and prevents the cascade of complications (immobility, venous thrombosis, deconditioning, depression) that follow hip fracture. A woman who fractures her hip has a 20% mortality rate at one year. Much of that mortality is cardiovascular.

The Integrated Management Framework

Managing the bone-artery axis requires a unified approach. Here is the clinical framework I use:

Step 1: Recognize the DEXA as cardiovascular information.

A T-score below -1.0 at any site in a postmenopausal woman should trigger cardiovascular risk assessment. Request a coronary artery calcium score if she has any additional risk factor: hypertension, diabetes, smoking history, family history of premature cardiovascular disease, or elevated Lp(a).

Step 2: Optimize calcium routing, not just calcium intake.

Total calcium intake (diet plus supplements) should not exceed 1,200 mg daily. Dietary calcium is preferred. If supplements are needed, use calcium citrate (better absorption, less GI intolerance) in divided doses of 500 mg or less.

Add vitamin K2 (MK-7), 180-360 mcg daily. Add vitamin D3 to achieve 25-OH-D levels of 40-60 ng/mL. This triad (calcium, D3, K2) directs calcium to bone and away from arterial walls.

Step 3: Address the hormonal driver.

Hormone replacement therapy (HRT) remains the only intervention that addresses the upstream cause of both osteoporosis and accelerated atherosclerosis. In the WHI, women who started estrogen within 10 years of menopause had reduced cardiovascular events and reduced fracture risk.

HRT is not appropriate for every woman. But the conversation should happen. The decision involves cardiovascular risk, breast cancer risk, quality of life, and patient preference. The decision should not be made by default avoidance. See our full discussion in Hormone Replacement Therapy: The Heart Decision.

Step 4: Treat osteoporosis with confidence.

Bisphosphonates reduce fracture risk without increasing cardiovascular risk. Denosumab (a RANKL inhibitor) also reduces fractures and has neutral cardiovascular effects. Do not withhold osteoporosis treatment out of cardiac fear. Untreated osteoporosis is a cardiovascular risk factor through fracture-mediated morbidity and mortality.

Step 5: Move.

Weight-bearing exercise builds bone and improves endothelial function. Resistance training increases bone mineral density and reduces arterial stiffness. Walking reduces cardiovascular events and fall risk. There is no pharmaceutical that accomplishes all three. Movement does.

Step 6: Test what matters.

Beyond the DEXA and CAC score, request: ApoB (better predictor of atherosclerotic risk than LDL-C), Lp(a) (genetic cardiovascular risk marker, elevated in 20% of the population), hs-CRP (vascular inflammation), and fasting insulin (metabolic health). These markers reveal the systemic environment in which both bone loss and vascular calcification occur.

What Your Physicians May Not Tell You

Most orthopedic surgeons do not think about coronary arteries. Most cardiologists do not think about bone density. The patient falls through the gap between specialties.

But the biology does not respect specialty boundaries. A T-score of -2.2 at age 54 is a cardiovascular warning sign. A CAC score of 200 in a woman with low bone density suggests failed calcium routing that may be modifiable. A postmenopausal woman on high-dose calcium supplements without K2 may be accelerating her vascular calcification while inadequately treating her osteoporosis.

The integrated view changes everything.

If you have been diagnosed with osteoporosis, you need cardiovascular evaluation. If you have significant coronary artery calcification, your bone density should be assessed. If you are taking calcium supplements, you need to know your total daily intake from all sources and you should be taking K2.

Your DEXA scan belongs in your cardiologist’s office. Your CAC score belongs in your endocrinologist’s file. Your next appointment is an opportunity to integrate what has been artificially separated.

Print this article. Bring it to your physician. Ask these questions:

1. What is my total daily calcium intake from food and supplements combined?
2. Should I add vitamin K2 to my regimen?
3. What is my coronary artery calcium score?
4. Is my vitamin D level best for both bone and cardiovascular health?
5. Should we discuss hormone replacement therapy given my bone and vascular status?

The answers may change your care. They may change your outcome. Your skeleton and your arteries are both trying to tell you something. Start listening.

Frequently Asked Questions

Does osteoporosis cause heart disease?

Osteoporosis does not directly cause heart disease in the way that a blocked coronary artery causes a heart attack. The relationship is more fundamental. Both conditions arise from the same hormonal deficit: estrogen loss at menopause. Estrogen maintains both endothelial function and bone density through distinct molecular mechanisms that fail simultaneously when hormone levels fall. In epidemiological studies, women with hip fractures have a 2.4-fold increased risk of cardiovascular death. This is not because the fracture triggers a cardiac event. It is because the same biological process that weakened the skeleton has been damaging the vasculature for years. Your bone density is a biomarker for vascular age. A low T-score should prompt cardiovascular evaluation, not just osteoporosis treatment.

Should I stop taking calcium supplements?

Do not stop abruptly without consulting your physician. The question is not whether calcium matters. Calcium is essential for bone health. The question is dose, source, and cofactors. Dietary calcium (dairy, fortified foods, leafy greens, sardines with bones) is preferred over supplements because it is absorbed more gradually and does not produce the acute calcium spikes that may promote vascular deposition. If you require supplements, use calcium citrate in divided doses of 500 mg or less. Ensure total daily calcium from all sources stays below 1,200 mg. Add vitamin K2 (MK-7 form, 180-360 mcg daily) to activate matrix Gla protein and direct calcium toward bone and away from arteries. Add vitamin D3 to maintain 25-OH-D levels of 40-60 ng/mL.

What is the calcium paradox?

The calcium paradox describes the clinical observation that calcium supplements intended to strengthen bones may instead deposit calcium in arterial walls. This occurs because calcium routing in the body depends on vitamin K2. Vitamin K2 activates two key proteins: osteocalcin, which incorporates calcium into bone matrix, and matrix Gla protein (MGP), which prevents calcium from depositing in soft tissues including arteries. Without adequate K2, both proteins remain inactive. Calcium floats in the bloodstream with nowhere to go, eventually depositing in vascular smooth muscle cells. The result is arterial stiffness and calcification while bones continue to lose mineral. The paradox is most pronounced in women with adequate dietary calcium who add supplements without K2.

Do bisphosphonates protect the heart?

Bisphosphonates have not been proven to protect the heart in randomized cardiovascular outcome trials. However, they do not appear to increase cardiovascular risk, and mechanistic data suggest potential benefit. Bisphosphonates inhibit the mevalonate pathway (similar to statins) and reduce vascular smooth muscle cell calcification in laboratory studies. Animal models show reduced aortic calcium content with bisphosphonate treatment. Human observational studies suggest neutral to mildly beneficial cardiovascular effects, including possible reductions in arterial stiffness. The more important point: women should not avoid treating osteoporosis out of cardiac concern. Hip fracture carries 20% one-year mortality, much of it cardiovascular in origin. Preventing fractures is cardiovascular risk management.

What tests should I request if I have osteoporosis?

Request a coronary artery calcium (CAC) score to directly visualize vascular calcification. Request carotid intima-media thickness (CIMT) if available. These imaging tests assess whether calcium is depositing in your arteries while leaving your bones. Request ApoB, which predicts atherosclerotic risk better than standard LDL cholesterol. Request Lp(a), a genetic cardiovascular risk marker elevated in 20% of the population that most physicians never measure. Request hs-CRP to assess systemic vascular inflammation. Request fasting insulin to evaluate metabolic health. Bring your DEXA scan results to your cardiologist. Your T-score is cardiovascular information. Treating your bone density in isolation from your vascular health misses the unified biology that connects both organ systems.